



BMT CTN PROTOCOL #0302

Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination with Corticosteroids

Significant Changes to Version 6.0 of the Protocol:

§2.3.1 – Inclusion Criteria Revised #4

The sentence was changed to read: (new text highlighted in italics) “Greater than or equal to 6 ~~2~~ years of age at the time of enrollment.” This was also updated in the Protocol Synopsis, Study Schema and Patient Informed Consent.